Back to Journals » OncoTargets and Therapy » Volume 7

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Authors Volpetti S, Zaja F, Fanin R

Received 11 February 2014

Accepted for publication 10 April 2014

Published 29 May 2014 Volume 2014:7 Pages 865—872


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Stefano Volpetti, Francesco Zaja, Renato Fanin

Division of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, Italy

Abstract: Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.

Keywords: pixantrone, aggressive non-Hodgkin B-cell lymphoma, relapsed/refractory

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]